BIOCAD launches the new manufacturing site in North Africa

30.11.2017

BIOCAD launches the new manufacturing site in North Africa

Russian biotechnology company BIOCAD and Moroccan pharmaceutical company Sothema Labs announced the launch of medicines derived using the technology provided by the Russian manufacturer into the North African market. The manufacturing of Russian biosimilars of rituximab and bevacizumab indicated for the treatment of cancer, approved in the first half of October 2017, will be based in Morocco. Besides Morocco, thеse biosimilars are planned to be marketed in Senegal, Gabon, and Côte d’Ivoire.

More Category: News
BIOCAD registered the first rituximab biosimilar in Bolivia and Honduras

06.06.2017

BIOCAD registered the first rituximab biosimilar in Bolivia and Honduras

In 2017, BIOCAD obtained a marketing authorization for its rituximab biosimilar in Bolivia and Honduras under the trade name USMAL. First shipments will start in the beginning of the third quarter of 2017. BIOCAD will be able to supply as much rituximab as needed for Bolivian and Honduran patients. Considering competitive price of the Russian biosimilar, estimated drug availability will double.

More Category: News
Supplies of Russian anti-cancer drug into Egypt will amount to $42.7 million

08.09.2015

Supplies of Russian anti-cancer drug into Egypt will amount to $42.7 million

On September 3, 2015 in St. Petersburg, Russia, an agreement was signed between a Russian innovative biotech company BIOCAD and the Egyptian company MED. PHARMA GROUP regarding supplies of anti-cancer drug Rituximab into Egypt.

More Category: News
Nobel laureate James Watson visited BIOCAD

23.06.2015

Nobel laureate James Watson visited BIOCAD

James Watson, who won the 1962 Nobel Prize in Biology and Medicine for the discovery of three-dimensional molecular structure of DNA, on June 20 visited the laboratories of the innovative biotech company BIOCAD.

More Category: News